Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study

详细信息    查看全文

• 作者：Hiroaki Ikezaki ; Norihiro Furusyo ; Satoshi Hiramine ; Kazuya Ura…
• 刊名：Archives of Virology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：161
• 期：3
• 页码：641-648
• 全文大小：466 KB
• 参考文献：1.Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342CrossRef PubMed
  2.Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562CrossRef PubMed
  3.Grebely J, Dore GJ (2011) What is killing people with hepatitis C virus infection? Semin Liver Dis 31:331–339CrossRef PubMed
  4.Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y et al (1997) Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25:697–701CrossRef PubMed
  5.Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523–1527CrossRef PubMed
  6.Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K et al (1995) Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 90:794–799PubMed
  7.Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450–456CrossRef PubMed
  8.Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, InC3 Study Group et al (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120PubMedCentral CrossRef PubMed
  9.Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E et al (2009) Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200:1216–1226PubMedCentral CrossRef PubMed
  10.Lemon SM (2010) Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 285:22741–22747PubMedCentral CrossRef PubMed
  11.Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D’Avolio A (2015) Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Arch Virol 160:2009–2017CrossRef PubMed
  12.Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J et al (2014) Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: a multicenter retrospective study in Japan. Hepatol Res 44:983–992CrossRef PubMed
  13.Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K et al (2013) Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 59:205–212CrossRef PubMed
  14.van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R et al (2011) Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One 6:e27555PubMedCentral CrossRef PubMed
  15.Clark PJ, Thompson AJ (2012) Host genomics and HCV treatment response. J Gastroenterol Hepatol 27:212–222CrossRef PubMed
  16.Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801PubMedCentral CrossRef PubMed
  17.Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H et al (2013) Plasma glycated albumin level and atherosclerosis: results from the Kyushu and Okinawa Population Study (KOPS). Int J Cardiol 167:2066–2072CrossRef PubMed
  18.Ihara T, Furusyo N, Hayashi T, Toyoda K, Murata M, Hayashi J (2013) A population-based epidemiology survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS). Arch Virol 158:2465–2472CrossRef PubMed
  19.Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M et al (2010) Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol 10:38PubMedCentral CrossRef PubMed
  20.Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324CrossRef PubMed
  21.Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H et al (2011) The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 49:1853–1860PubMedCentral CrossRef PubMed
  22.Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, Takova T et al (1999) Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 17:292–296CrossRef PubMed
  23.Zheng H, Li M, Chi B, Wu XX, Wang J, Liu DW (2015) IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 39:576–583CrossRef PubMed
  24.Rangnekar AS, Fontana RJ (2013) IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat 20:377–384PubMedCentral CrossRef PubMed
  25.Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immun 4:69–77CrossRef
  26.Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immun 4:63–68CrossRef
  27.Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177–181CrossRef PubMed
  28.Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T et al (2012) Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 57:1186–1192CrossRef PubMed
  29.Klein SL, Jedlicka A, Pekosz A (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 10:338–349CrossRef PubMed
  30.Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531CrossRef PubMed
  31.Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H (2006) TLR7 ligands induce higher IFN-alpha production in females. J Immun 177:2088–2096CrossRef PubMed
  32.Osterlund PI, Pietilä TE, Veckman V, Kotenko SV, Julkunen I (2007) IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immun 179:3434–3442CrossRef PubMed
  
• 作者单位：Hiroaki Ikezaki (1) (3)
  Norihiro Furusyo (1)
  Satoshi Hiramine (1)
  Kazuya Ura (1)
  Fujiko Mitsumoto-Kaseida (1)
  Koji Takayama (1)
  Motohiro Shimizu (1)
  Kazuhiro Toyoda (1)
  Eiichi Ogawa (1)
  Mosaburo Kainuma (1)
  Masayuki Murata (1)
  Jun Hayashi (2)
  
  1. Department of General Internal Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 8128582, Japan
  3. Nutritional Epidemiology Program, Jean Mayor USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, 02111, USA
  2. Kyushu General Internal Medicine Center, Hara-Doi Hospital, Fukuoka, 8138588, Japan
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Virology
  Medical Microbiology
  Infectious Diseases
  
• 出版者：Springer Wien
• ISSN：1432-8798

文摘

Hepatitis C virus (HCV) infection is a serious global health problem. Previous studies have suggested that the interleukin 28B (IL28B) rs8099917 genotype is related to spontaneous clearance of HCV in Caucasian populations. Our objective was to investigate the association of the IL28B rs8099917 genotype with spontaneous clearance of HCV by community-dwelling Japanese. A cross-sectional community-based population study of 993 Japanese residents was conducted. Based on anti-HCV antibody and HCV RNA levels, 50 subjects were assigned to the spontaneous-clearance group, 155 to the chronic-infection group, and 788 to the control group. Logistic regression analysis was done to examine the roles of the IL28B rs8099917 genotype and sex. To analyze the interactions between these factors, an “IL28B rs809991 genotype × sex” interaction term was included in the multivariate analysis. Significantly more subjects in the spontaneous-clearance group than in the chronic-infection group had the favorable IL28B rs8099917 genotype and were female. Multivariate logistic regression analysis extracted the favorable IL28B rs8099917 TT genotype (odds ratio [OR] 9.39; 95 % confidence interval [CI], 2.16–40.83, P = 0.003) and female sex (OR, 2.27; 95 % CI, 1.16–4.45, P = 0.017) as factors contributing to the spontaneous clearance of HCV. No significant interaction was found between the IL28B rs8099917 genotype and sex (P for interaction = 0.428). Both the favorable IL28B rs8099917 genotype and female sex were associated with the spontaneous clearance of HCV in this Japanese population.